Search

Your search keyword '"Molapo K"' showing total 3 results
Start Over Author "Molapo K"
3 results on '"Molapo K"'

1. Polyaniline based metal-organic framework composites for hydrogen fuel cells

Author

Ramohlola, Kabelo Edmond, Modibane, K D., Molapo, K. M., Lwuoha, E. I., Hato, M. J., Ramohlola, Kabelo Edmond, Modibane, K D., Molapo, K. M., Lwuoha, E. I., and Hato, M. J.

Abstract

In order to meet the great demand of energy supply globally, there must be a transition from dependency on fossil fuel as a primary energy source to renewable source. This can be attained by use of hydrogen gas as an energy carrier. In the context of hydrogen fuel cell economy, an effective hydrogen generation is of crucial significant. Hydrogen gas can be produced from different methods such as steam reforming of fossil fuels which emit greenhouse gases during production and from readily available and renewable resources in the process of water electrolysis. Hydrogen generated from water splitting using solar energy (photocatalysis) or electric energy (electrocatalysis) has attracted most researchers recently due to clean hydrogen (without emission of greenhouse gases) attained during hydrogen production. In comparison with photocatalytic water splitting directly using solar energy, which is ideal but the relevant technologies are not yet commercialized, electrolysis of water using catalyst is more practical at the current stage. The platinum group noble metals (PGMs) are the most effecting electrocatalysts for hydrogen evolution reactions (HER) but their scarcity and high cost limit their application. In this study, we presented the noble metal free organic-inorganic hybrid composites and their HER electrocatalysis performances were investigated. Polyaniline-metal organic framework (PANI/MOF) composite was prepared by chemical oxidation of aniline monomer in the presence of MOF content for hydrogen production. The properties of PANI, MOF and PANI/MOF composite were characterised for their structure and properties by X-ray diffraction (XRD), field-emission scanning electron microscopy (SEM), Fourier transform infrared (FTIR), thermogravimetric analysis (TGA), Raman, transmission electron microscopy (TEM), ultraviolet-visible spectroscopy (UV-vis), atomic absorption spectroscopy (AAS), square wave (SWV) and cyclic voltammetry (CV). There was a clear interaction of M, Sasol Inzalo foundation and National Research Foundation of South Africa

Published
2018

3. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.

Author

Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, Briner C, Kwatra G, Ahmed K, Aley P, Bhikha S, Bhiman JN, Bhorat AE, du Plessis J, Esmail A, Groenewald M, Horne E, Hwa SH, Jose A, Lambe T, Laubscher M, Malahleha M, Masenya M, Masilela M, McKenzie S, Molapo K, Moultrie A, Oelofse S, Patel F, Pillay S, Rhead S, Rodel H, Rossouw L, Taoushanis C, Tegally H, Thombrayil A, van Eck S, Wibmer CK, Durham NM, Kelly EJ, Villafana TL, Gilbert S, Pollard AJ, de Oliveira T, Moore PL, Sigal A, and Izu A

Subjects
Adenoviridae, Adolescent, Adult, Antibodies, Neutralizing physiology, COVID-19 epidemiology, COVID-19 immunology, COVID-19 Serological Testing, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines adverse effects, ChAdOx1 nCoV-19, Double-Blind Method, Humans, Middle Aged, South Africa, T-Lymphocytes physiology, Treatment Failure, Vaccine Potency, Young Adult, Antibodies, Neutralizing blood, COVID-19 prevention & control, COVID-19 Vaccines immunology, Immunogenicity, Vaccine, SARS-CoV-2
Abstract

Background: Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2 variants of concern, including the B.1.351 (501Y.V2) variant first identified in South Africa., Methods: We conducted a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) in people not infected with the human immunodeficiency virus (HIV) in South Africa. Participants 18 to less than 65 years of age were assigned in a 1:1 ratio to receive two doses of vaccine containing 5×10 10 viral particles or placebo (0.9% sodium chloride solution) 21 to 35 days apart. Serum samples obtained from 25 participants after the second dose were tested by pseudovirus and live-virus neutralization assays against the original D614G virus and the B.1.351 variant. The primary end points were safety and efficacy of the vaccine against laboratory-confirmed symptomatic coronavirus 2019 illness (Covid-19) more than 14 days after the second dose., Results: Between June 24 and November 9, 2020, we enrolled 2026 HIV-negative adults (median age, 30 years); 1010 and 1011 participants received at least one dose of placebo or vaccine, respectively. Both the pseudovirus and the live-virus neutralization assays showed greater resistance to the B.1.351 variant in serum samples obtained from vaccine recipients than in samples from placebo recipients. In the primary end-point analysis, mild-to-moderate Covid-19 developed in 23 of 717 placebo recipients (3.2%) and in 19 of 750 vaccine recipients (2.5%), for an efficacy of 21.9% (95% confidence interval [CI], -49.9 to 59.8). Among the 42 participants with Covid-19, 39 cases (95.1% of 41 with sequencing data) were caused by the B.1.351 variant; vaccine efficacy against this variant, analyzed as a secondary end point, was 10.4% (95% CI, -76.8 to 54.8). The incidence of serious adverse events was balanced between the vaccine and placebo groups., Conclusions: A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT04444674; Pan African Clinical Trials Registry number, PACTR202006922165132)., (Copyright © 2021 Massachusetts Medical Society.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results